Mitsubishi Chemical Safety Institute, a provider of various analyses, examinations and services for pharmaceutical companies, public institutions and chemical companies, is the first organization in Japan to become an Illumina CSPro (certified service provider). Illumina is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications.
Mitsubishi CSI offers its customers whole-genome and targeted-genotyping services using Illumina's Infinium and GoldenGate assays. Both of these leverage Illumina's proprietary BeadArray technology to provide customers with the ability to perform large-scale interrogation of the human genome, which enables them to cost-effectively fast forward their research and identify genetic variants linked to disease.
"For the last seven years, we have concentrated on the investigation of toxicogenomics and pharmacogenomics, and have consequently acquired an abundance of experience in the development of genomic analysis technologies," said Masaru Sekijima, general manager of Mitsubishi CSI's Advanced Medical Science Research Center. "As a result of this hard work, we are excited to become the first Illumina CSPro in Japan, making it possible to provide researchers with the level of high-quality genomic data customers have come to expect from Illumina," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze